Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Ligand

3 Overlooked Stocks Positioned for the Next Market Rotation

Oxford Club strategist Marc Lichtenfeld highlights diversification beyond tech, spotlighting Ligand Pharmaceuticals, Aflac and Atlantic Union Bankshares as healthcare, insurance and banking stocks gaining quiet momentum.

Gamble on Huge Gains with These 3 Best Biotech Stocks to Buy for 2026

Gamble on Huge Gains with These 3 Best Biotech Stocks to Buy for 2026

Investing in these three biotech stocks can offer investors with a high-risk profile the opportunity to generate outsized gains over the next decade.

3 'Strong Buy' Small-Cap Stocks to Snag Now for a Soft Landing

3 'Strong Buy' Small-Cap Stocks to Snag Now for a Soft Landing

Explore three small-cap stocks with 'Strong Buy' ratings that are poised for significant growth as economic conditions hint at a potential soft landing.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know

Editor's note: This story has been corrected to reflect that the FDA deferred action on Amicus Therapeutics' Biologics License Application.

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The European Commission (EC) has granted conditional marketing authorization (CMA) to BioMarin Pharmaceutical’s (NASDAQ:BMRN) lead asset ROCTAVIAN (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A (congenital Factor VIII deficiency) in adult patients. BioMarin shares traded as high as 2.28 percent, in a range of $91.39 to $93.68…

Barclays Maintains Overweight Rating for Ligand Pharmaceuticals: Here's What You Need To Know

Barclays has decided to maintain its Overweight rating of Ligand Pharmaceuticals (NASDAQ:LGND) and lower its price target from $165.00 to $157.00. Shares of Ligand Pharmaceuticals are trading up 1.79% over the last 24 hours, at $92.20 per share.

Merger Arbitrage Mondays - Berkshire Hathaway Acquires Insurer Alleghany For $11.6 Billion

Merger activity decreased last week with three new deals announced and two deals completed. Alleghany Corporation (NYSE: Y)

inkl

Read news from The Economist, FT, and more,
with one subscription

The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL

The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL

Here's a roundup of top developments in the biotech space over the last 24 hours:

Ligand To Spin-Off OmniAb Via Avista Capital-Backed SPAC Merger

Ligand To Spin-Off OmniAb Via Avista Capital-Backed SPAC Merger

Ligand Pharmaceuticals Inc (NASDAQ: LGND)

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

European Commission

Berkshire Hathaway

Food and Drug Administration

Microsoft Corporation

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Macular Degeneration

Places

407,167 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play